CoChat

SETD2: an epigenetic modifier with tumor suppressor functionality

Open access
Li, Jun, Duns, Gerben, Westers, Helga, Sijmons, Rolf, van den Berg, Anke, Kok, Klaas · 2016 · Oncotarget
Cited by 162

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

// Jun Li 1 , Gerben Duns 2 , Helga Westers 1 , Rolf Sijmons 1 , Anke van den Berg 3 and Klaas Kok 1 1 Department of Genetics, University of Groningen, University Medical Center Groningen, The Netherlands 2 Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, Canada 3 Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, The Netherlands Correspondence to: Klaas Kok, email: // Keywords : SETD2, H3K36me3, ccRCC, histone modification, tumor suppressor gene Received : February 24, 2016 Accepted : May 05, 2016 Published : May 14, 2016 Abstract In the past decade important progress has been made in our understanding of the epigenetic regulatory machinery. It has become clear that genetic aberrations in multiple epigenetic modifier proteins are associated with various types of cancer. Moreover, targeting the epigenome has emerged as a novel tool to treat cancer patients. Recently, the first drugs have been reported that specifically target SETD2 -negative tumors. In this review we discuss the studies on the associated protein, Set domain containing 2 (SETD2), a histone modifier for which mutations have only recently been associated with cancer development. Our review starts with the structural characteristics of SETD2 and extends to its corresponding function by combining studies on SETD2 function in yeast, Drosophila, Caenorhabditis elegans , mice, and humans. SETD2 is now generally known as the single human gene responsible for trimethylation of lysine 36 of Histone H3 (H3K36). H3K36me3 readers that recruit protein complexes to carry out specific processes, including transcription elongation, RNA processing, and DNA repair, determine the impact of this histone modification. Finally, we describe the prevalence of SETD2 -inactivating mutations in cancer, with the highest frequency in clear cell Renal Cell Cancer, and explore how SETD2-inactivation might contribute to tumor development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.9368

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 162

Metadata

Authors
Li, J., Duns, G., Westers, H., Sijmons, R., van den Berg, A., & Kok, K.
Venue
Oncotarget
Published
2016-05-14
Volume
7
Issue
31
Pages
50719-50734
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2361260139
Cited by
162
References
22
FWCI
9.33
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SETD2: an epigenetic modifier with tumor suppressor functionality. https://app.cochat.ai/papers/10.18632/oncotarget.9368
The paper
Li, J., Duns, G., Westers, H., Sijmons, R., van den Berg, A., & Kok, K. (2016). SETD2: an epigenetic modifier with tumor suppressor functionality. Oncotarget. https://doi.org/10.18632/oncotarget.9368

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.